Triage LVO

Brainomix
Brainomix Triage LVO is a notification-only, parallel workflow tool for use by hospital networks and trained clinicians to identify and communicate images of specific patients to a specialist, independent of standard of care workflow. Brainomix Triage LVO uses an artificial intelligence algorithm to analyze images for findings suggestive of a prespecified clinical condition and to notify an appropriate medical specialist of these findings in parallel to standard of care image interpretation. Identification of suspected findings is not for diagnostic use beyond notification. Specifically, the device analyzes CT angiogram images of the brain acquired in the acute setting, and sends notifications to a neurovascular specialist that a suspected large vessel occlusion (LVO) has been identified and recommends review of those images. Images can be previewed through a mobile application or via email. Brainomix Triage LVO is intended to analyze terminal ICA and MCA-M1 vessels for LVOs.
Information source: Vendor
Last updated: February 18, 2024

General Information

General
Product name Triage LVO
Company Brainomix
Subspeciality Neuro
Modality CT
Disease targeted Stroke
Key-features Notification of large vessel occlusions (MCA-M1 and ICA)
Suggested use

Technical Specifications

Data characteristics
Population Adult patients with suspicion of stroke
Input CTA
Input format DICOM
Output Notifications via a web user interface or mobile application. Compressed preview images meant for informational purposes only.
Output format
Technology
Integration Integration in standard reading environment (PACS), Stand-alone third party application, Stand-alone webbased
Deployment Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based, Hybrid solution
Trigger for analysis Automatically, right after the image acquisition, On demand, triggered by a user through e.g. a button click, image upload, etc.
Processing time

Regulatory

Certification
CE
No or not yet,
FDA 510(k) cleared , Class II
Intended Use Statements
Intended use (according to CE)

Market

Market presence
On market since 09-2023
Distribution channels
Countries present (clinical, non-research use)
Paying clinical customers (institutes)
Research/test users (institutes)
Pricing
Pricing model
Based on

Evidence

Evidence
Peer reviewed papers on performance
Non-peer reviewed papers on performance
Other relevant papers